For the year ending 2025-12-31, OLMA had -$91,179K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -162,451 |
| Depreciation and amortization expense | 490 |
| Non-cash lease expense | 1,176 |
| Non-cash interest income on marketable securities | -6,292 |
| Stock-based compensation expense, including employee stock purchase plan expense | 17,586 |
| Prepaid expenses and other current assets | 5,418 |
| Other assets and long-term deposits | 6,145 |
| Accounts payable | 4,598 |
| Other current liabilities | 10,984 |
| Operating lease liabilities | -1,244 |
| Net cash used in operating activities | -146,716 |
| Maturities of marketable securities | 344,962 |
| Purchases of marketable securities | 500,722 |
| Net cash used in investing activities | -155,760 |
| Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of 13,110 | 205,390 |
| Payment of issuance costs for shares issued under 2024 private placement | 6,514 |
| Proceeds from borrowings under credit facility (note 13) | 3,000 |
| Proceeds from exercise of stock options | 8,391 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,030 |
| Net cash provided by financing activities | 211,297 |
| Net (decrease) increase in cash and cash equivalents | -91,179 |
| Cash and cash equivalents at beginning of period | 139,480 |
| Cash and cash equivalents at end of period | 48,301 |
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)